BTW, I think we can forget about IMGN getting bought out any time soon for many reasons, mostly discussed. (e.g. license deals cheaper at the terms already negotiated.) But with even Lambert now selling off shares, as well as the more usual stock sales by Dan Junius and crew, looks like management insiders agree. They have their work cut out for the next two years, and hopefully the CytomXs arrangement is an indication that that is what they are doing. I agree with CH that share price will be eventually driven up as the Kadcyla revenues come in. These are honest revenues, earned the old fashion way, and the SP is less likely to get blown around by the winds of buyout speculation. Good investing and Happy New Year to all.
rev upside potential is probably limited to about $1BB under the current approvals, so best case for this year is about $20-30MM in sales revs + any other licensing deals, or milestones. Next year they could get some growth from additional country approvals. In 2016, if all goes well with the Kad trials for expansion, that's when revs will really start to ramp.
Hopefully, they will partner one of the in-house molecules and avoid additional dilutive financing, but probably not. They may need some cash to buy in with Biotest this year. IMGN needs pipeline results/progress, maybe AMGN will come through for them. 289 seems to be the best internal molecule, but no news is expected until at least year end and that probably means next year since they are always slow. Junius better do something good this year, or he will be out IMO.
No buyout with these clowns, but very interesting every time you see the slightest bit of strength in SP it gets sold hard. No reason for this to be back in the $14.70's after being at $15.30 this morning